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In type 2 diabetes, if good glycemic control is not maintained with oral antidiabetic 
agents (OADs), physicians often stop OADs and introduce twice-daily premixed 
insulins. In this 24-week, multicenter, open, parallel group study, 364 patients with 
type 2 diabetes and poor glycemic control using OADs were treated with once-daily 
insulin glargine (GLAR) with continued OADs (GLAR+OAD; glimepiride + metformin) 
or premixed 30% regular/70% human NPH insulin twice daily (70/30) alone. Insulin 
dosage was titrated to target fasting blood glucose (FBG) 100 mg/dL ( 5.6 mmol/L) 
with GLAR+OAD and to both FBG 100 mg/dL and pre-dinner BG 100 mg/dL with 
70/30, using a weekly forced-titration algorithm. To measure treatment satisfaction 
and change in treatment satisfaction, patients completed the Diabetes Treatment 
Satisfaction Questionnaire (DTSQs; status version) at baseline and endpoint and 
DTSQc (change version) at endpoint; 323 and 253 patients were included in the 
analysis of DTSQs and DTSQc scores, respectively. Maximum scores of 36.00 
(DTSQs) and 18.00 (DTSQc) indicated optimal treatment satisfaction and 
improvement in treatment satisfaction. Mean HbA1c decrease was significantly 
greater ( 1.64 vs 1.31%; p=0.0003) and more patients reached HbA1c 7.0% 
without nocturnal hypoglycemia (45.5 vs 28.6%; p=0.0013) in the GLAR+OAD versus 
70/30 group. At baseline, there was no difference in treatment satisfaction scores 
between the groups (GLAR+OAD: 26.91 vs 70/30: 26.26; p=0.3603). At study end, 
scores increased in both groups but changes were significantly greater in the 
GLAR+OAD vs the 70/30 group (+3.95 vs +2.32; p=0.0022). For DTSQc, the 
treatment satisfaction score at study end was higher in GLAR+OAD- versus 70/30-
treated patients (mean score 14.00 vs 11.54; p=0.0012). Initiating insulin therapy with 
the GLAR+OAD regimen is associated with a greater improvement in treatment 
satisfaction versus switching to twice-daily 70/30 alone. 
 
